Orbimed Advisors LLC Has $51.86 Million Stake in Abivax SA Sponsored ADR $ABVX

Orbimed Advisors LLC grew its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 26.6% in the first quarter, HoldingsChannel.com reports. The fund owned 465,700 shares of the company’s stock after buying an additional 97,800 shares during the quarter. Orbimed Advisors LLC’s holdings in Abivax were worth $51,856,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of ABVX. Nan Fung Trinity HK Ltd. raised its position in Abivax by 11.8% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock valued at $15,288,000 after purchasing an additional 12,000 shares during the last quarter. Total Clarity Wealth Management Inc. bought a new stake in shares of Abivax during the fourth quarter worth $1,247,000. Tudor Investment Corp ET AL acquired a new stake in shares of Abivax in the third quarter valued at $2,792,000. Brummer Multi Strategy AB acquired a new stake in shares of Abivax in the fourth quarter valued at $1,939,000. Finally, Harbor Capital Advisors Inc. bought a new position in shares of Abivax in the fourth quarter valued at about $1,193,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ABVX. Wolfe Research set a $136.00 price target on shares of Abivax in a research report on Wednesday, June 3rd. Leerink Partners upped their target price on shares of Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. Guggenheim reissued a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. Wedbush raised their price target on shares of Abivax from $90.00 to $110.00 and gave the company a “neutral” rating in a report on Tuesday, June 30th. Finally, Piper Sandler raised their price target on shares of Abivax from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.50.

Abivax Stock Performance

Abivax stock opened at $125.70 on Monday. The company has a market cap of $10.97 billion, a PE ratio of -24.13 and a beta of 0.87. Abivax SA Sponsored ADR has a 1 year low of $65.67 and a 1 year high of $148.83. The company’s 50-day moving average is $117.99 and its two-hundred day moving average is $118.22.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. Research analysts forecast that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.